| Similar Articles |
|---|
 |
Bio-IT World
May 19, 2004
Barbara Depompa |
Turning Sugar into Science The landmark building that housed the New England Confectionery Company in Revere, Mass. is being transformed into the new headquarters for the Novartis Institutes for BioMedical Research.   |
BusinessWeek
June 11, 2009
Kerry Capell |
Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials. |
Bio-IT World
January 13, 2003
John Dodge |
Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets. |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
Pharmaceutical Executive
July 1, 2012 |
Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale? |
Pharmaceutical Executive
July 1, 2013
Looney et al. |
Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what? |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
November 2005
Mark D. Uehling |
The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
Pharmaceutical Executive
July 3, 2007
Walter Armstrong |
Take Me to Your Leader Turnover in the top 10 pharmas has new CEOs racing to reinvent the way their companies do business. Running a large pharmaceutical company has becoming immensely complex, and requires a broad set of management skills. Even then, a CEO may never see a beloved molecule approved for drughood. |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
The Motley Fool
April 21, 2005
Stephen D. Simpson |
Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space. |
The Motley Fool
January 19, 2006
Stephen D. Simpson |
Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space. |
Bio-IT World
February 10, 2003
Malorye Branca |
The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success. |
The Motley Fool
October 23, 2006
Brian Lawler |
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
Bio-IT World
Dec 2006/Jan 2007
John Russell |
Novartis' Answer to Harry Potter Imagine a magic wand able to instantly materialize novel, safe, and effective drugs. No such device exists, of course, but Novartis has a distant cousin of sorts: the UltraLink is an immensely powerful text-mining tool and knowledge management platform. |
Pharmaceutical Executive
October 1, 2005 |
Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership. |
The Motley Fool
July 16, 2010
Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. |
Pharmaceutical Executive
November 1, 2008 |
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring? |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
Pharmaceutical Executive
March 12, 2012
William Looney |
Novartis: LEADing in Emerging Markets With growth as its guiding light, Novartis has big plans for the emerging markets. CEO Joe Jimenez tells us what it will take the company to best the competition. |
The Motley Fool
February 10, 2011
Brian Orelli |
Breathe Easier, Join the Competition Novartis' strategy is a good one. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
BusinessWeek
January 7, 2010
Capell & Doherty |
What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business. |
Bio-IT World
August 13, 2002
Kevin Davies |
Curtailing the Cancerous Cell The highly touted drug Gleevec unleashed new hope in the battle against cancer. Now a group of new drugs, working on the same principle, are showing even greater promise in treating leukemia. |
The Motley Fool
March 16, 2005
Cliff Malings |
Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. |
The Motley Fool
March 29, 2006
Stephen D. Simpson |
Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note. |
The Motley Fool
July 17, 2006
Stephen D. Simpson |
Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
Chemistry World
January 24, 2013
Andrew Turley |
Vasella to leave Novartis in August Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company. |
The Motley Fool
October 22, 2007
Brian Lawler |
No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
